• Home

  • Solutions for

  • Our Brands

  • Services

  • News & Events

  • About Us

  • More

    SINGAPORE

    MALAYSIA

    Contact Us

    Tel (Main): +65 - 6264 4628 | Fax: +65 - 6264 4625

    Life Science
    Solutions for Cell Biology and Analyses

     

    Circulating Tumour Cell Isolation

    IsoFlux

     

    The IsoFlux System enables molecular analysis of circulating tumor cells (CTCs) and other rare cell types. Using Fluxion’s proven microfluidic technology, the platform recovers CTCs from biological samples with the highest level of sample integrity. The recovered cells move immediately to downstream clinical research applications including mutation detection, next-generation sequencing, FISH, and gene expression.

     

    Highest CTC recovery - Independent data has shown superior target cell recovery compared to currently-available cell enrichment devices.

     

    Most flexible system - Have your own isolation marker? Want the flexibility to add in multiple capture antibodies? IsoFlux makes it easy to define your own criteria using open access bead chemistry.

     

    Superior sample integrity - Good analysis starts with a high quality sample. In addition to high levels of recovery, IsoFlux samples have low background, low elution volume, and high viability.

     

    Diverse analysis options - Analysis of CTCs requires multiple downstream techniques to look at DNA, RNA, and protein. IsoFlux samples come out of the instrument ready to use in the most common platforms such as arrays, qPCR, and next-generation sequencing.

     

    The IsoFlux System utilizes a proprietary microfluidic technology and immunomagnetic beads to isolate rare cells from biological samples. Typical applications include analysis of circulating tumor cells (CTCs), cancer stem cells, stem cells, and immune cells.

     

    Once these rare cells are enriched using IsoFlux, they are immediately ready for downstream analysis using next-generation sequencing (NGS), qPCR, FISH, IHC, and related analytical approaches.

    More Info

    SINGAPORE